Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Investors can access the live webcast and archived replay on the company Events page; registered participants may receive dial-in numbers and a unique PIN to ask questions.
Positive
- None.
Negative
- None.
News Market Reaction – LXRX
On the day this news was published, LXRX declined NaN%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves, and only LRMR appeared in momentum scans, moving down 5.87% without news, suggesting LXRX action around the earnings date is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | Offering closed | Negative | -2.4% | Closed public offering and private placement with intended R&D use. |
| Jan 30 | Offering priced | Negative | -19.4% | Priced large public offering and concurrent private placement. |
| Jan 29 | Offering announced | Negative | -19.4% | Announced proposed underwritten public offering and private placement. |
| Jan 23 | Corporate milestone | Neutral | -3.4% | Planned Nasdaq closing bell ceremony for 30th anniversary. |
| Jan 21 | Clinical update | Positive | +19.1% | FDA raised no objections to advancing pilavapadin into Phase 3. |
Recent history shows negative reactions to equity offerings and a strong positive move on favorable clinical progress, indicating sensitivity to dilution and value-creating pipeline milestones.
Over the past months, Lexicon reported multiple financing events, including public offerings and a concurrent private placement, which saw shares decline between 2.44% and 19.44%. A corporate milestone event, its 30th anniversary Nasdaq closing bell, had a modest -3.41% reaction. In contrast, a positive clinical update on pilavapadin following a successful End-of-Phase 2 FDA meeting coincided with a 19.08% gain. Against this backdrop, the newly announced Q4 2025 earnings date serves as a scheduling update rather than a value-defining catalyst by itself.
Market Pulse Summary
This announcement sets March 5, 2026 as the date for reporting Q4 2025 results, with a conference call at 8:30 a.m. ET. Recent history shows shares reacting strongly to financings and a key clinical update, so investors may focus on how the upcoming report contextualizes recent capital raises and Phase 3 plans. Key items to watch include cash position, spending trends, and any updates on pilavapadin and the broader pipeline.
AI-generated analysis. Not financial advice.
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals (LXRX) report fourth quarter 2025 results?
How can investors join the Lexicon (LXRX) March 5, 2026 earnings webcast?
What time is the Lexicon (LXRX) Q4 2025 conference call on March 5, 2026?
Will Lexicon (LXRX) provide a replay of the March 5, 2026 earnings webcast?
Can shareholders ask questions during the Lexicon (LXRX) March 5, 2026 earnings call?
